- Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
- Nearly 160 Million Americans Harmed by Another’s Drinking, Drug Use
- 1 in 4 Americans Now Struggling to Cover Medical Costs
- Getting Fitter Can Really Help Keep Dementia at Bay
- Skin Patch Could Monitor Your Blood Pressure
- There May Be a Better Way to Treat Hematoma Brain Bleeds
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Living in Space Won’t Permanently Harm Astronauts’ Thinking Skills
- Kids’ Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
- Human Cell Atlas Will Be ‘Google Maps’ for Health Research
New Device Treats Superficial Varicose Veins
The VenaSeal closure system has been approved by the U.S. Food and Drug Administration to treat superficial varicose veins in the leg that appear close to the skin and cause an unsightly and sometimes painful condition.
The product, administered by a trained professional, is designed to seal the affected veins, preventing the pooling of blood in these vessels. It was clinically evaluated in a study of more than 200 participants, comparing it to another treatment called radio-frequency ablation.
“The trials showed the device to be safe and effective for vein closure for the treatment of symptomatic superficial varicose veins of the legs,” the FDA said Friday in a news release.
The VenaSeal system should not be used in people with a known sensitivity to the system’s adhesive, or in those with inflamed veins due to blood clots or infection. The most common side effects included vein inflammation and burning and tingling in the treatment area, the agency said.
The VenaSeal system is manufactured by Covidien LLC, in Morrisville, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.